A Randomized, Single-Blind, Endoscopic Evaluation Of Upper GI Mucosal Damage Induced By PL-2200 Versus Aspirin In Healthy Volunteers

Trial Profile

A Randomized, Single-Blind, Endoscopic Evaluation Of Upper GI Mucosal Damage Induced By PL-2200 Versus Aspirin In Healthy Volunteers

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Aug 2015

At a glance

  • Drugs Aspirin/phosphatidylcholine (Primary) ; Aspirin
  • Indications Embolism and thrombosis; Myocardial infarction; Stroke
  • Focus Adverse reactions
  • Sponsors PLx Pharma
  • Most Recent Events

    • 11 May 2010 Status changed from active, no longer recruiting to completed.
    • 28 Apr 2010 Positive results announced, according to a PLx Pharma media release.
    • 01 Apr 2009 Planned end date (1 Jul 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top